A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
Hoffmann-La Roche
Hoffmann-La Roche
Pfizer
Astellas Pharma Inc
Merck Sharp & Dohme LLC
Incyte Corporation
Akeso
DualityBio Inc.
AstraZeneca
Arcus Biosciences, Inc.
Arcus Biosciences, Inc.
Novartis
AstraZeneca
AstraZeneca
Genentech, Inc.
Gilead Sciences
AstraZeneca
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
ImmunityBio, Inc.
Revolution Medicines, Inc.
Agenus Inc.
Merck Sharp & Dohme LLC
Eli Lilly and Company
Bristol-Myers Squibb
ImmunityBio, Inc.
Daiichi Sankyo
Gilead Sciences
Merck Sharp & Dohme LLC
Gilead Sciences
Verastem, Inc.
AbbVie
SynerGene Therapeutics, Inc.
NovoCure Ltd.
Hummingbird Bioscience
Ono Pharmaceutical Co. Ltd
Corcept Therapeutics
iOnctura
Biotheus Inc.
Takara Bio Inc.
Trishula Therapeutics, Inc.
Merck Sharp & Dohme LLC
MedImmune LLC